• Member News

Congenica and SFI Research Centre FutureNeuro Unite to Deliver More Accurate Diagnoses for Genetic Epilepsy

New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland.

Horizon Discovery enters into license agreement with US immuno-oncology company

• Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies, demonstrating Horizon’s ability to generate revenues from internally derived IP • Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic reference standards, and cell therapy

Positive results achieved in ReViral's Phase IIa RSV challenge study

ReViral, a UK-based biotech company focused on developing novel compounds targeting respiratory syncytial virus (RSV), today announced successful results from its Phase IIa placebo-controlled challenge trial in healthy adult subjects infected intranasally with respiratory syncytial virus (RSV).

Congenica Signs Strategic Digital Health Contracts During Official UK-China Trade Mission

Congenica, the global provider of clinical genomics interpretation software, signed a series of significant memorandums of understanding (MOUs) with leading Chinese companies and healthcare providers at a UK-Chinese Future of Medicine trade event in Beijing, China. The meeting was held in conjunction with the State visit of Prime Minister May.

Domainex appoints Dr Kevin Doyle as Head of Chemistry

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. His appointment strengthens the expanding team of international scientists at its research facilities on Chesterford Research Park, based in Cambridge, UK, which has grown by more than 50% in the past 18 months.

MedAware Systems Launches Comprehensive Apheresis Research Database

MedAware Systems, Inc. announced today it is launching the world’s most comprehensive database of evidence on Apheresis, available through its SOHInfo™ division. Data have been meticulously extracted from over 2,300 clinical trials, cohort studies, registries, reviews and other published works, spanning medical journals worldwide. The Company continuously updates this database as new studies are published.

New bio-incubator and life-science accelerator capability launches at the Babraham Research Campus

Accelerate@Babraham is supported by AstraZeneca, MedImmune, One Nucleus, and RxCelerate.

Are you the most innovative company in Oxfordshire? Apply now for The Oxford Science Park Innovation Award, part of OXBA 2018

Oxford, UK, 24 January 2018 - Oxfordshire companies which have progressed valuable innovations over the past three years can apply now for The Oxford Science Park Innovation Award, one of 2018's Oxfordshire Business Awards. Open to companies of any size and from any sector, the deadline for applications is March 2. This is the third year that The Oxford Science Park, one of the UK's leading parks for science and technology companies, has sponsored the Innovation Award.

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.

Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business

Today Cambridge-based clinical genomics company Congenica announced the appointment of its new CEO David Atkins, Ph.D.. He will lead the company’s ambitious international expansion and drive further rapid growth, including a roll-out of its commercial operations across Europe, the USA and Asia. Dr Atkins has over 25 years’ experience as a global leader in diagnostics and healthcare businesses, with extensive commercial experience in markets in North America, EMEA, Asia and Latin America.